

08/16/01

To: All Sales Representatives Selling Paxil cc: RVPs
TSMs
From: Zachary Hawkins Paxil DSMs
RMSs
Paxil Product Management

Study Title "Efficacy of Paroxetine in the Treatment of Adolescent Major Depression: A Randomized, Controlled Trial"

Author(s) Martin B. Keller, M.D.

Journal J. AM. ACAD. CHILD ADOLESC. PSYCHIATRY 2001

Date Vol Pages 2001, July, Vol. 40:7: 762-772

Significance of article This "cutting-edge," landmark study is the first to compare efficacy of an SSRI and a TCA with placebo in the treatment of major depression in adolescents. Paxil demonstrates REMARKABLE Efficacy and Safety in the treatment of adolescent depression.

- Key Points
- The treatment of depression in adolescents is an area of burgeoning interest. Unfortunately, few well controlled, large scale, randomized clinical trials have been conducted in this population. (pg 762, col. 2, par 1)
 - National Comorbidity Survey indicates lifetime prevalence rate of 15.3% for adolescent major depression, comparable with a 17% lifetime prevalence in adults. (pg 763 col 1 par 1)
 - Comorbid anxiety disorders were present in 19% to 28% of subjects. (pg 765 col 1 par 1) COMORBIDITY!
 - Paxil was significantly more effective than placebo with regard to achievement of both HAM-D total score \leq 8, CGI score of 1 (very much improved) or 2 (much improved), and improvements in the depressed mood items of the HAM-D and the K-SADS-L.
 - Roughly two-thirds (63.3%) of the subjects on Paxil, 50% of Imipramine subjects, and 46% of placebo subjects achieved remission (a HAM-D total score of \leq 8) at endpoint based on the LOCF Dataset. (Table 2) Among patients who completed 8 weeks of treatment, 76% of Paxil subjects, 64.3% of Imipramine subjects, and 57.6% of placebo subjects achieved remission. (OC Dataset) FIG. 1
 - Nearly half of the subjects in the Paxil group remained at the initial starting dose of 20mg/day (48%). Mean dose at study endpoint for Paxil was 28.0 mg and for Imipramine was 205.8 mg. (pg 766 col 2 par 3)
 - Paxil was generally well tolerated in this adolescent population.

End of Page 1 of 2

01px

DO NOT PRODUCE WITHOUT ATTORNEY APPROVAL

PAR000815403

GSKCO-0003-000426

CONFIDENTIAL: Produced pursuant to subpoena dated February 6, 2004 issued by United States Attorney, District of Colorado.

GCO007-0429

LAM: Find Comm Journal Cover 001 300

For use with physicians and can be left with them. Approved by legal, medical and regulatory

For distribution to physicians, but may not be discussed. Approved by legal, medical and regulatory

FYI Article will be stamped: This article is for pharmaceutical consultants information only. Do not use it with, or distribute to, physicians.

Choose only one of these categories.

File (type an X in only one box)

and most adverse events were not serious. The most common adverse events occurred at rates that were similar to rates in the placebo group (pg 768 col 1 par 2)

- Adverse cardiovascular effects were not observed in subjects treated with Paxil. In contrast, tachycardia, postural hypotension, prolongation of QT intervals during imipramine therapy resulted in treatment discontinuation in one third (13.7%) of the 31.5% subjects who stopped treatment prematurely with the TCA.
- In conclusion, the findings of this study provide evidence of the efficacy and safety of Paxil in the treatment of adolescent depression. Here's another example of GlaxoSmithKline's commitment to Psychiatry by bringing forth "cutting edge" scientific data. Paxil is truly a REMARKABLE product that continues to demonstrate efficacy, even in this understudied population.

DO NOT PRODUCE WITHOUT ATTORNEY APPROVAL

PAR00081540

GSKCO-0003-000427

CONFIDENTIAL: Produced pursuant to subpoena dated February 6, 2004 issued by United States Attorney, District of Colorado.